Glycated Hemoglobin (HbA1c) Testing Market Size, Share and Growth Outlook, 2026

Glycated Hemoglobin (HbA1c) Testing Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Glycated Hemoglobin (HbA1c) Testing Market size is forecast to increase from $2.77 Billion in 2026 to $4.58 Billion in 2034 at a CAGR of 6.5% between 2026 and 2034.

The Glycated Hemoglobin (HbA1c) Testing market report provides detailed analysis and outlook of Glycated Hemoglobin (HbA1c) Testing segments including By Product & Service (Laboratory-based Analyzers, Point-of-Care, Reagents & Consumables), By Technology (Chromatography, Immunoassays, Enzymatic Assays, Capillary Electrophoresis), By Application (Diabetes Diagnosis, Long-term Glycemic Monitoring), By End-User (Diagnostic Laboratories, Hospitals, Clinics & Physician Offices, Homecare) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Glycated Hemoglobin (HbA1c) Testing Industry Overview

Point-of-Care HbA1c Testing Accuracy Across Global Healthcare Settings

The glycated hemoglobin (HbA1c) testing industry is advancing through rigorous global validation of point-of-care (POC) diagnostic systems used in decentralized diabetes care. A multi-country cross-sectional evaluation conducted by FIND (Geneva) and the European Reference Laboratory for Glycohemoglobin assessed commercial HbA1c platforms in low- and middle-income countries using capillary and venous whole blood samples. The study confirmed strong alignment of Siemens DCA Vantage and Abbott Afinion 2 systems with National Glycohemoglobin Standardization Program (NGSP) criteria, reinforcing their reliability for field-based diabetes monitoring. However, systems such as i-SENS A1Care and HemoCue HbA1c 501 demonstrated clinically significant analytical bias at elevated HbA1c levels, impacting diagnostic consistency in real-world settings.

Analytical Variability and Hemoglobin Variant Detection in High-Throughput Platforms

Modern HbA1c testing systems are increasingly evaluated for their ability to detect rare hemoglobin variants that can distort glycemic readings. Comparative studies across high-throughput analyzers including Arkray HA-8190V, Tosoh G11, Bio-Rad D-100, and Sebia Capillarys highlight significant differences in variant detection performance. Platforms with dedicated variant modes, such as Arkray HA-8190V and Bio-Rad D-100, successfully identified 100% of tested abnormal hemoglobin samples, while other standard operating configurations showed negative bias without proper alerting mechanisms. This variability emphasizes the importance of variant-aware analytical modes in preventing misinterpretation of glycemic control in genetically diverse populations.

Regulatory Standards and DCCT-Traceable Diagnostic Compliance Frameworks

The HbA1c testing industry is tightly regulated under updated clinical frameworks established by major diabetes authorities. The American Diabetes Association (ADA) has reinforced strict diagnostic thresholds requiring all laboratory HbA1c assays to maintain traceability to the Diabetes Control and Complications Trial (DCCT) reference standard through NGSP certification. The guidelines further specify that in conditions affecting red blood cell turnover—such as pregnancy, G6PD deficiency, or HIV therapy—alternative plasma glucose-based diagnostic criteria must override HbA1c readings. These regulations define the operational boundaries for in vitro diagnostic manufacturers and ensure consistency across global diabetes diagnostic systems.

Decentralized Diabetes Monitoring and Infrastructure Expansion in LMICs

The expansion of HbA1c testing into community and decentralized healthcare environments is shaping procurement strategies for diagnostic infrastructure. Field validation studies are providing critical performance benchmarks that guide the selection of POC analyzers for resource-limited settings. This supports broader adoption of standardized HbA1c testing systems in primary care environments, improving early detection and long-term diabetes management across underserved populations while maintaining alignment with global reference standards.

Glycated Hemoglobin (HbA1c) Testing Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Glycated Hemoglobin (HbA1c) Testing market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- F. Hoffmann-La Roche Ltd., Abbott Laboratories, Siemens Healthineers, Danaher Corporation (Beckman Coulter), Bio-Rad Laboratories, Inc., Thermo Fisher Scientific Inc., Bayer AG, Trinity Biotech PLC, Tosoh Corporation, EKF Diagnostics. The Glycated Hemoglobin (HbA1c) Testing market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Glycated Hemoglobin (HbA1c) Testing industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Glycated Hemoglobin (HbA1c) Testing Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Glycated Hemoglobin (HbA1c) Testing companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Glycated Hemoglobin (HbA1c) Testing markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Glycated Hemoglobin (HbA1c) Testing Market Competitive Benchmarking and Company Analysis

Leading companies in Glycated Hemoglobin (HbA1c) Testing industry include- F. Hoffmann-La Roche Ltd., Abbott Laboratories, Siemens Healthineers, Danaher Corporation (Beckman Coulter), Bio-Rad Laboratories, Inc., Thermo Fisher Scientific Inc., Bayer AG, Trinity Biotech PLC, Tosoh Corporation, EKF Diagnostics. The Glycated Hemoglobin (HbA1c) Testing market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Glycated Hemoglobin (HbA1c) Testing Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Glycated Hemoglobin (HbA1c) Testing market remains one of the strongest-performing segments in the country.
The US Glycated Hemoglobin (HbA1c) Testing Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Glycated Hemoglobin (HbA1c) Testing market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Glycated Hemoglobin (HbA1c) Testing industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Glycated Hemoglobin (HbA1c) Testing markets

Canada's strong Glycated Hemoglobin (HbA1c) Testing sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Glycated Hemoglobin (HbA1c) Testing market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Glycated Hemoglobin (HbA1c) Testing Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Glycated Hemoglobin (HbA1c) Testing market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Glycated Hemoglobin (HbA1c) Testing population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Glycated Hemoglobin (HbA1c) Testing industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Glycated Hemoglobin (HbA1c) Testing market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Glycated Hemoglobin (HbA1c) Testing sales through 2034

France Glycated Hemoglobin (HbA1c) Testing companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Glycated Hemoglobin (HbA1c) Testing Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Glycated Hemoglobin (HbA1c) Testing distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Glycated Hemoglobin (HbA1c) Testing Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Glycated Hemoglobin (HbA1c) Testing market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Glycated Hemoglobin (HbA1c) Testing industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Glycated Hemoglobin (HbA1c) Testing industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Glycated Hemoglobin (HbA1c) Testing Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Glycated Hemoglobin (HbA1c) Testing market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Glycated Hemoglobin (HbA1c) Testing market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Glycated Hemoglobin (HbA1c) Testing Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Glycated Hemoglobin (HbA1c) Testing Market Segmentation

By Product & Service
Laboratory-based Analyzers
Point-of-Care
Reagents & Consumables
By Technology
Chromatography
Immunoassays
Enzymatic Assays
Capillary Electrophoresis
By Application
Diabetes Diagnosis
Long-term Glycemic Monitoring
By End-User
Diagnostic Laboratories
Hospitals
Clinics & Physician Offices
Homecare

Top Companies in Glycated Hemoglobin (HbA1c) Testing Industry

F. Hoffmann-La Roche Ltd.
Abbott Laboratories
Siemens Healthineers
Danaher Corporation (Beckman Coulter)
Bio-Rad Laboratories, Inc.
Thermo Fisher Scientific Inc.
Bayer AG
Trinity Biotech PLC
Tosoh Corporation
EKF Diagnostics

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Rise of Functional and Clinical-Grade Skincare

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025

Market Update

Low MOQ, High-Mix Production Models for Indie & DTC Brands

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025